[이코노믹리뷰=곽예지 기자] On the 16th, Humasys (205470), a company specializing in on-site rapid inspection, announced on the 16th that it had signed a 10 billion won treasury stock repurchase trust contract.
This treasury share agreement is aimed at stabilizing stock prices and enhancing shareholder value. The contract period will be held through Korea Investment & Securities for six months from March 16 to September 16 this year.
Humasys CEO Cha Jeong-hak said, “The acquisition of treasury stock not only stabilizes the company’s stock price, but also builds confidence in the company’s continued growth potential as a leading company in the diagnostic kit market. To this end, we plan to additionally lay the foundation for sustainable growth by expanding investments in various on-site diagnostic fields such as molecular diagnostics, biochemical diagnostics, and remote diagnostics.”
In addition to the treasury stock repurchase trust contract, Humasys plans to make continuous efforts to improve shareholder-friendly policies and shareholder value, such as proposing a cash dividend agenda at the regular shareholders’ meeting to be held this month.
Meanwhile, Humasys recently obtained KGMP approval from the Ministry of Food and Drug Safety for a new manufacturing plant in Uiwang, Gyeonggi-do. Together with the existing Anyang and Gunpo factories, it is producing up to 50 million tests per month of rapid antigen diagnostic kits and self-test kits for COVID-19.
